Document Detail

Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry.
MedLine Citation:
PMID:  20491016     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion in patients with ST elevation myocardial infarction (STEMI). Abciximab is a well established adjunct to primary PCI. The proper timing of abciximab administration in STEMI patients has been investigated in randomised trials, registries and metanalysis, providing conflicting results.
METHODS: Consecutive data on STEMI patients, transferred for primary PCI in hospital/ambulance STEMI networks between November 2005 and January 2007, from 15 PCI centres in seven European countries was gathered together for a one-year long-term clinical observation (93% rate of completeness).
RESULTS: Data from 1,650 patients was collected in the EUROTRANSFER Registry. Abciximab was administered to 1,086 patients (66%), 727 patients received early (at least 30 minutes prior to first balloon inflation) abciximab (EA), and another 359 patients received late abciximab (LA). One year mortality was 5.8% in the EA group vs 10.3% with LA (p = 0.007). Adjustment for propensity score methods for EA administration did not change the results, still providing a favourable outcome for the EA group (p = 0.004). It was also revealed that only a minority of patients (36%) were treated within the 90-minute recommended time window from first medical contact to PCI (and 60% for the 120-min time delay).
CONCLUSIONS: Patients transferred for primary PCI in STEMI hospital networks showed lower rates of death in long-term one-year clinical follow-up when treatment with abciximab was started early.
Zbigniew Siudak; Tomasz Rakowski; Artur Dziewierz; Magnus Janzon; Ralf Birkemeyer; Justyna Stefaniak; Łukasz Partyka; Krzysztof Zmudka; Dariusz Dudek
Related Documents :
19530156 - The paclitaxel-eluting coroflex please stent study (pecops i): the 3-year clinical foll...
10149106 - Procedural variables associated with eventual long term angiographic success in patient...
17697816 - Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting...
9490236 - Prevention of restenosis after angioplasty in small coronary arteries with probucol.
24097226 - Femoral vein thrombosis after right-sided electrophysiological procedures.
9128116 - Internal carotid pseudo-occlusion: early and late results.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Kardiologia polska     Volume:  68     ISSN:  0022-9032     ISO Abbreviation:  Kardiol Pol     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-21     Completed Date:  2010-08-20     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  0376352     Medline TA:  Kardiol Pol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  539-43     Citation Subset:  IM    
Institute of Cardiology, Collegium Medicum, Jagiellonian University, Krakow, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angioplasty, Balloon, Coronary*
Antibodies, Monoclonal / administration & dosage*
Combined Modality Therapy
Drug Administration Schedule
Europe / epidemiology
Follow-Up Studies
Immunoglobulin Fab Fragments / administration & dosage*
Middle Aged
Myocardial Infarction / diagnosis,  mortality,  therapy*
Platelet Aggregation Inhibitors / administration & dosage*
Registries / statistics & numerical data*
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; X85G7936GV/abciximab
Comment In:
Kardiol Pol. 2010 May;68(5):544-5   [PMID:  20491017 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comment to article Ostre uszkodzenie nerek po operacjach kardiochirurgicznych zwieksza ??miertelno??...
Next Document:  [EUROTRANSFER Registry - still a lot to do to optimize treatment of myocardial infarction with eleva...